Home » Stocks » Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. (ALDX)

Stock Price: $7.64 USD 0.05 (0.66%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 295.16M
Revenue (ttm) n/a
Net Income (ttm) -49.26M
Shares Out 38.63M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $7.64
Previous Close $7.59
Change ($) 0.05
Change (%) 0.66%
Day's Open 7.66
Day's Range 7.25 - 7.71
Day's Volume 266,831
52-Week Range 1.48 - 8.70

More Stats

Market Cap 295.16M
Enterprise Value 243.89M
Earnings Date (est) Apr 1, 2021
Ex-Dividend Date n/a
Shares Outstanding 38.63M
Float 35.30M
EPS (basic) -1.75
EPS (diluted) -1.73
FCF / Share -1.41
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.70M
Short Ratio 2.50
Short % of Float 4.81%
Beta 2.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.55
Revenue n/a
Operating Income -48.66M
Net Income -49.26M
Free Cash Flow -42.48M
Net Cash 51.26M
Net Cash / Share 1.33
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -41.79%
ROE -82.02%
ROIC -163.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$26.83*
(251.18% upside)
Low
15.0
Current: $7.64
High
33.0
Target: 26.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-63.07-39.70-22.49-18.70-11.99-7.27-3.68
Net Income-60.83-38.89-22.34-18.70-12.09-5.1913.06
Shares Outstanding27.1121.6915.9211.358.633.820.32
Earnings Per Share-2.24-1.79-1.40-1.65-1.40-3.09-17.61
Operating Cash Flow-44.98-29.86-19.22-15.15-9.31-4.78-1.71
Capital Expenditures-0.01-0.26-0.02-0.01-0.09-0.01-
Free Cash Flow-44.99-30.12-19.25-15.16-9.40-4.79-1.71
Cash & Equivalents73.3693.6042.9524.9127.598.533.26
Total Debt14.75-1.341.321.291.251.27
Net Cash / Debt58.6193.6041.6123.6026.307.271.99
Assets75.5295.0944.1725.1928.208.793.74
Liabilities27.448.474.573.543.332.505.65
Book Value48.0886.6239.6021.6524.886.28-40.22
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aldeyra Therapeutics, Inc.
Country United States
Employees 10
CEO Todd C. Brady

Stock Information

Ticker Symbol ALDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALDX
IPO Date May 2, 2014

Description

Aldeyra Therapeutics, a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.